Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Kidney Dis ; 69(5): 637-646, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28089478

RESUMO

BACKGROUND: Few studies have examined the treatment and outcome of adult-onset minimal change nephrotic syndrome (MCNS). We retrospectively studied 125 patients who had MCNS with onset in either adulthood or late adolescence. Presenting characteristics, duration of initial treatment and response to treatment, relapse patterns, complications, and long-term outcome were studied. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Patients with new-onset nephrotic syndrome 16 years or older and a histologic diagnosis of MCNS in 1985 to 2011 were identified from pathology records of 10 participating centers. OUTCOMES: Partial and complete remission, treatment resistance, relapse, complications, renal survival. RESULTS: Corticosteroids were given as initial treatment in 105 (84%) patients. After 16 weeks of corticosteroid treatment, 92 (88%) of these patients had reached remission. Median time to remission was 4 (IQR, 2-7) weeks. 7 (6%) patients initially received cyclophosphamide with or without corticosteroids, and all attained remission after a median of 4 (IQR, 3-11) weeks. 13 (10%) patients reached remission without immunosuppressive treatment. One or more relapses were observed in 57 (54%) patients who received initial corticosteroid treatment. Second-line cyclophosphamide resulted in stable remission in 57% of patients with relapsing MCNS. Acute kidney injury was observed in 50 (40%) patients. Recovery of kidney function occurred almost without exception. Arterial or venous thrombosis occurred in 11 (9%) patients. At the last follow-up, 113 (90%) patients were in remission and had preserved kidney function. 3 patients with steroid-resistant MCNS progressed to end-stage renal disease, which was associated with focal segmental glomerulosclerosis lesions on repeat biopsy. LIMITATIONS: Retrospective design, variable treatment protocols. CONCLUSIONS: The large majority of patients who had MCNS with onset in adulthood or late adolescence were treated with corticosteroids and reached remission, but many had relapses. Cyclophosphamide resulted in stable remission in many patients with relapses. Significant morbidity was observed due to acute kidney injury and other complications. Progression to end-stage renal disease occurred in a few patients and was explained by focal segmental glomerulosclerosis.


Assuntos
Injúria Renal Aguda/epidemiologia , Corticosteroides/uso terapêutico , Ciclofosfamida/uso terapêutico , Glomerulosclerose Segmentar e Focal/epidemiologia , Imunossupressores/uso terapêutico , Falência Renal Crônica/epidemiologia , Nefrose Lipoide/tratamento farmacológico , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Seguimentos , Glomerulosclerose Segmentar e Focal/fisiopatologia , Humanos , Falência Renal Crônica/fisiopatologia , Masculino , Pessoa de Meia-Idade , Nefrose Lipoide/epidemiologia , Nefrose Lipoide/fisiopatologia , Recuperação de Função Fisiológica , Recidiva , Indução de Remissão , Remissão Espontânea , Estudos Retrospectivos , Trombose/epidemiologia , Trombose Venosa/epidemiologia , Adulto Jovem
2.
Ned Tijdschr Geneeskd ; 153: B350, 2009.
Artigo em Holandês | MEDLINE | ID: mdl-19857290

RESUMO

Iron-deficiency is one of the most prevalent worldwide deficiencies. In the western world, chronic, mostly occult, blood loss is a frequent cause. However, in up to 30% of patients an underlying cause is never found during routine investigations. We describe two male patients aged 20 and 62 years and a 77-year-old woman with mainly fatigue and iron-deficiency showing no abnormalities on endoscopy. In these patients, infection with H. pylori was regarded as the major cause of iron deficiency, and there was lasting normalization of iron status and haemoglobin after successful eradication therapy. Although the underlying mechanism still remains to be established, we recommend investigation for H. pylori infection and appropriate treatment in case of unexplained iron-deficiency. In a number of patients, eradication results in a clinically significant improvement of both iron-balance and status.


Assuntos
Anemia Ferropriva/etiologia , Antibacterianos/uso terapêutico , Infecções por Helicobacter/complicações , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori , Idoso , Anemia Ferropriva/diagnóstico , Feminino , Infecções por Helicobacter/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...